Colorectal cancer vaccine - Shanghai Haixin BiotechnologyAlternative Names: APDC - Shanghai Haixin Biotechnology; autologous tumor lysates pulsed human dendritic cells vaccine - Shanghai Haixin Biotechnology
Latest Information Update: 05 Jan 2016
At a glance
- Originator Shanghai Haixin Biotechnology
- Developer Second Military Medical University; Shanghai Haixin Biotechnology
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Colorectal cancer
Most Recent Events
- 17 Feb 2005 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) in China (IV)